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Background: With improved survival rates, short- and long-term respiratory complications of premature birth are
increasing, adding significantly to financial and health burdens in the United States. In response, in May 2010, the
National Institutes of Health (NIH) and the National Heart, Lung, and Blood Institute (NHLBI) funded a 5-year $18.5
million research initiative to ultimately improve strategies for managing the respiratory complications of preterm
and low birth weight infants. Using a collaborative, multi-disciplinary structure, the resulting Prematurity and
Respiratory Outcomes Program (PROP) seeks to understand factors that correlate with future risk for respiratory
morbidity.
Methods/Design: The PROP is an observational prospective cohort study performed by a consortium of six clinical
centers (incorporating tertiary neonatal intensive care units [NICU] at 13 sites) and a data-coordinating center
working in collaboration with the NHLBI. Each clinical center contributes subjects to the study, enrolling infants with
gestational ages 23 0/7 to 28 6/7 weeks with an anticipated target of 750 survivors at 36 weeks post-menstrual age.
In addition, each center brings specific areas of scientific focus to the Program. The primary study hypothesis is that
in survivors of extreme prematurity specific biologic, physiologic and clinical data predicts respiratory morbidity
between discharge and 1 year corrected age. Analytic statistical methodology includes model-based and
non-model-based analyses, descriptive analyses and generalized linear mixed models.
Discussion: PROP incorporates aspects of NICU care to develop objective biomarkers and outcome measures of
respiratory morbidity in the <29 week gestation population beyond just the NICU hospitalization, thereby leading
to novel understanding of the nature and natural history of neonatal lung disease and of potential mechanistic and
therapeutic targets in at-risk subjects.
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Approximately 1 out of every 9 live births in the United
States occurs prematurely. Preterm birth is associated
with serious respiratory illnesses that are especially prob-
lematic in the first two years of life. Better understanding
of the etiologies and risk factors for respiratory disease
of prematurity is essential to effectively prevent and treat
these disorders. The risks of developing respiratory dis-
ease in preterm infants are inversely related to their ges-
tational age at birth (GA), with a diagnosis of
bronchopulmonary dysplasia further increasing this risk.
Yet, at any given GA, reliable clinical markers to quan-
tify severity of future disease or predict which infants
will develop long-term respiratory complications are
lacking. Objective biochemical or physiologic measures
for either clinical or research purposes are also rare. In
recognition of the gaps in definitional, operational and
mechanistic understanding, the Prematurity and Re-
spiratory Outcomes Program (PROP) was created to
characterize and develop a means of predicting clinically
meaningful and persistent pulmonary disease of prema-
turity, in the context of current neonatal intensive care
practices [1]. It is a multi-disciplinary, six-center, 13-site
organization (Table 1) fostering the collaboration of neo-
natologists, pulmonologists, and basic scientists working
to identify biomarkers of one-year respiratory morbidity
and mortality in a cohort of more than 750 extremely
preterm infants. The data gathered through this project
will also be used to investigate mechanisms contributing
to respiratory disease of the preterm newborns and to
provide high-resolution phenotyping of disease severity
for use in clinical applications and future trials.
This report of the study protocol details the design of
the PROP study and illustrates the breadth of data and
biospecimens that will be available at the end of the
one-year follow-up period. It also suggests a multiplicity
of future studies investigating complications andTable 1 Single center programs and specific projects
Program center # Clinical
sites
Project objectives
University of Pennsylvania 0 Data Coordinating Center f
Duke University/Indiana University 2 Gastrin-releasing peptide a
University of Rochester/University
at Buffalo
2 Functional and lymphocyti
infants
Cincinnati Children’s Hospital
Medical Center
3 Biomarkers of immunologic
University of California, San
Francisco
3 Influence of the nitric oxid
Vanderbilt University 2 Immaturity and genetic var
modulation of BPD phenot
Washington University 1 Influence of the enteric mitherapeutic interventions for the respiratory complica-
tions of prematurity.
Methods/Design
The PROP required each Center to submit a single-site
biomarker proposal along with a potential multi-site
shared protocol for measuring respiratory phenotypes
and outcomes of extremely preterm infants. The center-
specific studies are reflected in the project objectives in
Table 1, while the multicenter protocol was a collabora-
tive effort.
The PROP structure is depicted in Figure 1. In October
2011, an additional center composed of 2 clinical sites
(Indiana University and Duke University) was added to
the program based on the alignment of their research
objectives. Each clinical center and the Data Coordin-
ating Center (DCC) are represented on the Steering
Committee, with each center contributing to the data
collection, coordination and oversight of the multicen-
ter components. The DCC manages clinical report
forms, provides support for standardization of defini-
tions, data collection, quality monitoring and analysis.
Oversight is provided by an NHLBI appointed steering
committee chair, NIH officials, and an observational
and safety monitoring board (OSMB) with representa-
tives from neonatology, pediatric pulmonology and
biostatistics. The steering committee holds a confer-
ence call every 2 weeks, meets in-person twice yearly and
in addition, holds working meetings at the American
Thoracic Society and Pediatric Academic Society confer-
ences. The committee identifies and resolves issues, en-
courages the centers to present updates of their
projects, and determines future directions for the con-
sortium. Working groups developed the initial proto-
cols for biospecimen acquisition (Additional file 1),
maternal and neonatal database elements (Additional
files 2, 3, 4, 5 and 6) and respiratory measurements#
Enrolled
or the PROP N/A
nd bronchopulmonary dysplasia 105
c markers of respiratory morbidity in hyperoxic preterm 142
function and preterm respiratory outcomes 111
e pathway and inflammation on preterm respiratory outcomes 161
iation in urea cycle-nitric oxide and glutathione pathways
ype
184
crobiome on the genesis of bronchopulmonary dysplasia 132
Figure 1 Prematurity and Respiratory Outcomes Program (PROP) Structure and Logo.
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provided regular monitoring of the standardization and
quality of the measurements. The publications committee
developed guidelines for authorship and a process for
review and approval of manuscripts and abstracts prior to
submission for publication or presentation.
Additional funding from the National Institute of
Child Health and Human Development (NICHD)
through the Best Pharmaceuticals for Children Act
(BPCA) allowed expansion of the database collection to
include comprehensive medication administration data
(in hospital and post-discharge) and the creation of a
“PROP Scholars” program to fund competitive and in-
novative PROP-related subprojects for trainees and
junior faculty.
Multicenter protocol development
Primary and secondary outcomes
A key scientific aim of PROP is to identify early clinical,
physiologic, or biochemical biomarkers during the NICU
hospitalization that can predict respiratory morbidity
through 1 year of age. The primary outcome for PROP
is the presence or absence of substantial post-
prematurity respiratory disease, a composite obtainedfrom longitudinal data in the first year post NICU dis-
charge. Morbidity in four domains is examined: respira-
tory symptoms, medication use, hospitalizations and
dependence on technology during the first year of life
and results of infant pulmonary function testing at
1 year of age in a subset of participants. Mortality from
cardiorespiratory cause is incorporated as well.
Secondary outcomes include death, near-term “BPD”
status, the PROP Physical Exam Score and a Respiratory
Morbidity Severity Score at one year, summarizing sever-
ity across the morbidity domains.
Protocol
The inclusion and exclusion criteria are listed in Table 2
and the protocol is outlined in Figure 2. The protocol is
designed to provide the highest resolution phenotyping
possible with the mandate to use standardized, widely
applicable, non-invasive methods for data and biospeci-
men collections that will reflect a continuum of disease
and care.
The sample size for the multicenter study was pre-
specified to include 750 surviving infants at a 36-week
postmenstrual age (PMA) time-point. Power calculations
consider a simplified binary outcome of persistent
Table 2 Inclusion/Exclusion criteria
Inclusion criteria
- 23 0/7 to 28 6/7 weeks using best obstetrical estimate
- 7 days of age or less at enrollment
Exclusion criteria
- Concern for viability
- Structurally significant congenital heart disease
- Structural abnormalities of the upper airway, lungs or chest wall
- Congenital malformations or syndromes that adversely affect life
expectancy or cardio-pulmonary development
- Family unlikely to be available for long-term follow-up
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physiologic, or other biomarker. The sample size of 750,
assuming a missing rate of 10% (5% due to late deaths
and 5% due to loss to follow up), allows a power of >80%
to detect a significant association at an odds ratio of 1.25
or higher for each one standard deviation increase in
the biomarker associated with respiratory disease presence.
This calculation assumes no measurement errors and
no correlation between the biomarker and other covari-
ates, and a conservative 40% rate of persistent respira-
tory disease.
Clinical data collection
All data are prospectively collected from birth using
medical record review and family interviews and include:
maternal and infant demographics, clinical data and co-
morbidities, daily infant respiratory, nutritional, and
medication data throughout the NICU stay. Mothers
also provide family history of atopy and asthma (See
data collection forms in Additional files 2, 3, 4, 5 and 6).
After discharge, a series of telephone questionnaires,Figure 2 PROP Study Protocol Time Line spans from birth to one yea
*Tracheal aspirate samples were collected if the infant was intubated and c
from oxygen to room air (21% oxygen, the “Room Air Challenge”) or from
NIRA: Non-invasive respiratory assessment; GERD: gastroesophageal reflux dbased on the Tucson Children’s Respiratory Study [2-6]
and the Breathing Outcomes Study (a secondary study
to the NICHD Neonatal Research Network Surfactant
Positive Airway Pressure and Pulse Oximetry Trial) [7-9]
are conducted. The questionnaires assess domains of re-
spiratory morbidity at 3, 6, 9 and 12 months corrected
age. At 6 and 12 months, a survey of environmental re-
spiratory irritant exposures and an assessment for gas-
troesophageal reflux disease, using the modified Infant
Gastroesophageal Reflux Questionnaire Revised, are
completed [10]. An in-person visit for a physical exam
and history is performed at 1 year corrected age.
Families are also consented for continuing contact for
anticipated longer-term studies.
Biospecimen archive
Gaps in our understanding of chronic and long-term re-
spiratory sequelae of prematurity are widened by a gen-
eral lack of clinically derived biospecimens to be used to
identify biomarkers and mechanisms of disease. A sub-
committee established standardized procedures for sam-
ple collection and central processing, and protocols for
accessing the resulting biorepositories (Additional files 1
and 9). Samples collected are cross-sectional or longitu-
dinal (Figure 2). Saliva specimens from infants and
parents are collected at study entry for future DNA ex-
traction. Saliva/mouth swabs obtain high quality infant
DNA, but may require re-collection to achieve sufficient
quantity for exome or genome-wide analyses (>5 micro-
grams of DNA). Tracheal fluid samples are collected if
the infant is intubated and clinically requires suctioning.
Tracheal aspirates and urine specimens are obtained on
enrollment, 3 days after enrollment, and at 14 and 28
postnatal days. Early (≤1 week) specimens may reflect
initial injury, developmental and genetic biosyntheticr of corrected age collecting health data and biospecimens.
linically required suctioning. #Physiologic challenge testing was either
room air to 15% oxygen (“hypoxia challenge”) depending on status.
isease; iPFT: infant pulmonary function testing.
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targeted therapy, while the later time points (>1 week)
may reflect responses to oxidative stress, infection, in-
flammation, nutritional state, and tissue repair [11]. The
DCC maintains details about the biospecimens for qual-
ity control and to assist in their identification for distri-
bution. The Steering Committee formally defined a
mechanism to submit and evaluate biospecimen access
request proposals, with PROP-related investigative teams
receiving short-term priority. Applications for access to
the specimens will be reviewed for justification and
feasibility of the proposed assays, and are expected to
demonstrate independent funding to generate and
analyze resulting data.
Assessments of respiratory function (physiologic
biomarkers)
A unique feature of the PROP protocol is the inclusion
of physiologic biomarkers as potential predictors of re-
spiratory morbidity, based on the established value of
premorbid respiratory function as an independent risk
factor for wheezing and asthma in later life for term
infants [2,5]. Standard infant pulmonary functions tests
(PFTs) simulating adult-like spirometry can be performedFigure 3 Non-Invasive Respiratory Assessment (NIRAs) Decision Diagr
plethysmography (RIP) (with associated tests of oxygen saturations during
by corrected age, degree of respiratory support required and anticipation oduring the first postnatal year but are not feasible in
NICU. Additionally, these tests are time and labor in-
tensive, and not easily performed on a large scale. As
alternative measures for the entire cohort, a set of
non-invasive respiratory assessments (NIRAs) was se-
lected, including respiratory inductance plethysmogra-
phy (RIP), pulse oximetry recordings during sleep,
bronchodilator response, and oxygen reduction chal-
lenges (Figure 3, Table 3). The NIRAs are performed
at 34–41 weeks PMA if the subject is not mechanically
ventilated or receiving non-invasive positive pressure
ventilation. Studies are performed within one week of
anticipated discharge and, if possible, without a nasal
feeding tube in place. The timing for pre-discharge
testing is purposefully linked to anticipated discharge
instead of a given gestational age as a reflection of
achieved physiologic stability.
Specific NIRAs performed depend on the clinical sta-
tus at the anticipated discharge date and include mea-
surements of thoracoabdominal asynchrony and the
ratio of time to peak tidal expiratory flow to expiratory
time (Tpef/Te) using RIP [12-19]. To assess potential
airway reactivity, RIP is performed before and after in-
haled albuterol [12,19]. Continuous pulse oximetry dataam. The indicated oxygen reduction tests and respiratory inductive
sleep and oral feeding) were preformed on individual days determined
f hospital discharge.
Table 3 PROP Noninvasive respiratory assessments (NIRA) and relationship to physiologic measures
NIRA Measurements Potential mechanism
Respiratory Inductance
Plethysmography
Tidal breathing analysis Altered lung compliance and airway obstruction
- Phase angle
- Tpef/Te
Desaturations after short apnea Reduced functional residual capacity
Response to inhaled albuterol Increased smooth muscle tone
- Phase angle
- Tpef/Te
Physiologic Challenges Oxygen and flow reduction to
ambient air
Alveolar-arterial oxygen gradient, control of breathing, standard
definition of “BPD”
Hypoxic challenge test with 0.15
FiO2
V/Q mismatch, control of breathing, “respiratory reserve”
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analyzed for the number and pattern of desaturations as-
sociated with spontaneous short (<20 sec) apneas. This
non-invasive test indirectly infers that lung volume is
adequate and can be maintained. Increased frequency of
mild oxyhemoglobin desaturations with short apneas
can reflect reduced functional residual capacity [19]. The
PROP analysis assesses the number of episodes per mi-
nute of quiet sleep in which the oxygen saturation
(SpO2) decreases 4% or more, the fall in SpO2 per sec-
ond of apnea, and the lowest SpO2.
For comparison purposes with existing classifications
of BPD [19-24], data regarding use of supplemental oxy-
gen at 36 ± 1 weeks PMA and results of a standardized
oxygen requirement challenge test are collected. If the
infant fails the challenge test or is not eligible based on
degree of respiratory support or clinical care team as-
sessment of instability, and if the infant is still in the
hospital, another assessment and challenge is attempted
at 40 ± 1 weeks (Figure 3). The protocol developed by
Walsh, et al. was modified to discriminate between ef-
fects of FiO2 and flow (the latter potentially generating
stimulation or positive distending pressure, thus affect-
ing oxygenation [23]). The infants are studied in quiet
sleep at least 30 minutes after feeding. If oxygen satura-
tions are maintained ≥90% for at least 15 minutes on the
prescribed nasal cannula support, the FiO2 is weaned to
0.21 in decrements of 0.2 at 5-minute intervals. The flow
is then reduced in 1 liter/min (LPM) decrements at 10-
minute intervals until it is less than 1.5 LPM, followed
by 50% decrements to a minimum of 0.125 LPM. After a
10-minute observation period, the cannula is removed
and the infant is monitored in room air for 1 hour. Fail-
ure at any point in the testing is defined as SpO2 < 90%
for 5 continuous minutes, SpO2 < 80% for 15 seconds, or
apnea for >20 seconds. The latter, or bradycardia of <80
beats/min for >10 seconds, are recorded as adverse
events. The infants are returned to the original support
at the end of testing.To further characterize the respiratory reserve of
infants who are breathing ambient air or who pass a
room air challenge test at 36 weeks, a 15-minute trial
of FiO2 of 0.15 (the equivalent of the O2 partial pres-
sure at 8000 feet altitude) was originally performed
prior to discharge. This “hypoxia challenge” is recom-
mended for individuals with cardiopulmonary condi-
tions in anticipation of air travel [25,26]. After baseline
data collection, if SpO2 was continuously ≥90%, a mon-
itored respiratory oxyhood is placed over the sleeping
infant with either a commercially available mixture of
15% oxygen with nitrogen or an on-site blended mix-
ture of medical oxygen and nitrogen resulting in an
FiO2 of 0.15. Criteria for failure of this test included
SpO2 < 85% for 60 consecutive seconds, SpO2 < 80% for
15 seconds, bradycardia (HR <80 beats/min for 10 sec)
or apnea persistent despite mild tactile stimulation. In-
terim review of results performed in 2013, demon-
strated a test rate of 34% (221 of 643 discharged to
home) and a failure rate of 78% with a median age of
36 weeks PMA at testing. Although no significant ad-
verse events occurred, the high failure rate raised
concerns about the ability of this challenge to provide
additional insight into respiratory physiology and
prompted the Observational Safety Monitoring Board
to discontinue the hypoxia test in December 2013.
No severe adverse events (need for CPR or mechanical
ventilation or increase in FiO2 by 0.1 above baseline)
have occurred during any of the NIRA assessments.
Four mild adverse events occurred during the study: one
apnea (>20 seconds) with a RIP, and three bradycardia
events, one with the hypoxia challenge and two with the
room air challenge. No tachycardia (>200 beats per
minute for >1 hour), or need for increase flow or FiO2
above baseline have occurred after any test.
Standardized physical examination
The Respiratory Distress Assessment Instrument (RDAI)
and the Respiratory Assessment Change Score quantify
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[25-30] with good inter-observer reliability [31]. The
PROP Physical Examination Score uses some elements
of the RDAI and incorporates other elements that reflect
the effects of chronic respiratory impairment, such as
growth and the development of digital clubbing. This
standardized physical exam focuses on anthropometrics,
vital signs, and respiratory system signs and is performed
coincident with RIP (36–40 weeks) and again at 1 year
corrected age.
Examiners are all trained and certified to perform the
standardized exam. With the infant in the supine pos-
ition and awake, heart rate, respiratory rate and highest
sustained oxyhemoglobin saturation are recorded over
one minute. If the infant is still requiring supplemental
oxygen (≤1.5 LPM) at the 12-month visit, the child is
placed in room air for 2 minutes for measurement pur-
poses only. End-inspiratory chest circumference, pres-
ence of suprasternal, intercostal or subcostal retractions,
thoraco-abdominal asynchrony and accessory muscle
use are recorded. Chest auscultation determines the
presence, localization, and characteristics of crackles or
wheezes. The cardiac point of maximal ventricular im-
pulse is determined by palpation and the presence of
digital clubbing is noted. Physical exam components are
entered into single point and longitudinal algorithms as
a composite score for later analysis.
Infant pulmonary function testing (iPFT)
Prematurity is associated with poorer lung function in
infancy and childhood: even infants with minimal or no
oxygen requirement at discharge demonstrate airflow
obstruction and gas trapping compared to full-term con-
trols [32-35]. To evaluate lung growth and respiratory
dysfunction, six sites trained and certified to perform
iPFTs will test 180 PROP infants. Infants eligible for
iPFT receive chloral hydrate sedation to perform tidal
breathing, single occlusion resistance/compliance mea-
sures, plethysmography and spirometry by the raised
volume rapid thoracoabdominal compression (RVRTC)
technique using the nSpire Infant Pulmonary Lab
(nSpire, Inc, Longmont, CO) or BabyBox device (Carefu-
sion Respiratory Diagnostics,Yoma Linda, CA) [36]. The
raised volume technique is repeated after albuterol ad-
ministration [37]. Measurements are listed in Additional
file 8: Table S1. All techniques meet American Thoracic
Society/European Respiratory Society standards [36,38-40].
Expert reading of the iPFT recordings is performed at two
sites (Indiana University, University of North Carolina at
Chapel Hill).
Data collection, management and storage systems
A centralized Oracle database system (Oracle Corporation,
Redwood Shores, CA) is maintained by the DCC. Localsites contribute data using a web-based interface.
Individual centers retain access to their own data through
customized downloads from Oracle that are transferred
systematically to a REDCap (Research Electronic Data
Capture) web-based database management tool [41]. In
addition, some centers maintain an independent, custom-
ized, local REDCap database that is specific to their single
site data acquisition. These data management options pro-
vide flexibility, separate layers of data quality control and
simple and complete local access to Center specific data.
The combination of a centralized database and local tools
and storage result in a balance between the needs for a
stable and secure core structure and flexible end-user
applications.
Analytic approaches and considerations
The primary outcome of “post-prematurity respiratory
disease” requires that infants demonstrate morbidity in
one of the four post NICU discharge domains (respira-
tory medications; hospitalizations for cardiopulmonary
cause; coughing, wheezing, or other respiratory symp-
toms; or home technology dependence) in at least 2 time
frames (at approximately 3 month intervals). Death from
a respiratory cause is also included. Secondary analyses
will allow the modification of these criteria to assess the
sensitivity of the chosen definition for the outcome. Al-
ternate analyses will also consider a repeated measures
analysis for the individual-visit level data using mixed ef-
fect logistic regression and generalized estimating
equations.
Analysis approaches will include multiple individual
statistical tests at the univariate and multivariate levels
utilizing the accumulated clinical and physiologic data to
evaluate potentially complex associations, to control for
confounding factors, and to assess contributions to out-
comes. Since the PROP is composed of 6 designated
clinical research centers affiliated with a total of 13
NICUs, the analysis will be adjusted for clinical sites.
The impact of significant missing data on outcomes will
be assessed and reported in secondary analyses.
While in some cases it will be appropriate to provide
some protection against detecting false positive results,
adjustments of significance levels using multiple com-
parison techniques, which would lessen the chance of
detecting potentially important biomarkers and other
risk factors for severity of respiratory disease will be
used sparingly [42]. These more liberal approaches to
dealing with multiple comparisons were considered for
hypothesis generating rather than hypothesis testing
aims. Therefore, significance values related to odds ratios
for biomarker prediction of the one-year outcome will
generally be used as indicators for postulated risk factors.
Although PROP clinical sites are dispersed across the
country, they may not be representative of NICUs in any
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that might impact the results will be assessed to examine
factor imbalances within the PROP cohort and whether
factor variations reflect the general population. The sen-
sitivity of our approaches to changes in these factors will
allow us to adjust or acknowledge discrepancies in any
statements or inferences from PROP.
Study approval and oversight
The multi-center PROP protocol and consent forms
were evaluated by the University of Pennsylvania IRB
(initial approval date July 20, 2011) as a greater than
minimal risk protocol due to the oxygen reduction test-
ing and albuterol administration. In addition IRBs at
each PROP center determined level of risk, based on
their local interpretation. The IRBs further addressed is-
sues of the future use of archived biospecimens, inclu-
sion of an opt-in/opt-out approach for separate
components of the protocol, including for DNA collec-
tion, and for future research, and methods to ensure
subject privacy and protection. The program follows a
strict monitoring plan for reporting adverse events and
is monitored by an independent Observational and
Safety Monitoring Board (OSMB) appointed by the
Director of NHLBI. The complete list of IRB approvals
and protocol numbers can be found in Appendix 2.
Training and quality control
Since study inception, the DCC has held bi-weekly
training webinars with the research team from each site
to ensure uniform approaches to data and specimen
collection and respiratory assessments. Regular survey
of the data by the DCC also permits targeted interven-
tion at sites that may be facing challenges in executing
some aspects of the protocol. In the early phases of en-
rollment, site visits by a team that included a PROP
Principal Investigator, a consortium-identified lead re-
search coordinator and lead respiratory therapist,
pulmonologist, and representatives from NHLBI and
the DCC reinforced these procedures and developed
best practices to disseminate and maximize uniformity
across the consortium, similar to that done with other
complex multicenter protocols [43-45].
Interactions of single center and multicenter protocols
Each of the six non-DCC PROP Study Centers is re-
sponsible for a “single center” peer-reviewed project
(Table 1). These projects share a common goal of identi-
fying biomarkers of respiratory morbidity over the first
year of life and an emphasis on preterm infants <29 weeks
gestation. The common database of demographics,
clinical NICU events, and respiratory examination
and survey results reflecting 1-year outcomes can be
used by each single center in the evaluation of theirbiomarker(s) of choice. Single center projects can recruit
additional infants, including some born at >29 weeks and
can obtain additional history or biospecimens not col-
lected by the multicenter consortium. The Steering
Committee decided that data and specimens relevant to a
single center’s studies only would be entered and main-
tained locally.
Challenges and resolution
Several questions arose in the development and imple-
mentation of the study, all of which were brought to the
Steering Committee for discussion and resolution. For
example, delays and inconsistency in enrollment across
sites prompted extensive examination of consent and en-
rollment procedures through webinars and site visits.
Approaches based on the more successful centers’ prac-
tices were implemented and resulted in the targeted en-
rollment across the consortium.
As PROP investigators continue to formulate new
ideas, the issue of who “owns” the multicenter data and
specimens has also created tension regarding allocation
of resources between the current needs of the PROP,
such as analysis of existing data and publication of major
outcomes, versus the need for preliminary data to de-
velop funding proposals to pursue these new hypotheses.
The Steering Committee decides on an individual basis
how to balance these priorities. Access to biospecimens
and linked data undergoes a similar review and
prioritization process.
The maintenance of data and the biorepository beyond
the PROP funding period are currently being resolved.
As new funding proposals are developed that utilize col-
lected biospecimens, support for personnel, specimen
retrieval, and quality control procedures are being
incorporated into the budgets and scientific plans.
Summary and progress through enrollment
Enrollment began August 3, 2011 and concluded
November 1, 2013 (Figure 4); the follow-up to one year
corrected age is expected to continue through mid-2015.
Consent rates ranged from 42.4% to 80.9% by center, or
63.0% for the consortium, for a total enrollment of 835
participants. The most frequent reasons for exclusion or
not approaching parents are highlighted in Figure 4. The
demographics of the enrolled cohort are depicted in
Table 4 and do not differ significantly from those not en-
rolled (data not shown).
The biospecimen archive of DNA, tracheal aspirate
and urine specimens, the physiologic testing, and
breadth of the investigative teams prompted several
ancillary studies that have added dimensions to the ori-
ginal PROP design (Table 5). Most notable was the de-
velopment of the PROP Scholars’ program through
support obtained from the NICHD BPCA program. This
Figure 4 PROP Consort Diagram. * ‘Other’ reasons for not approaching parents for consent included maternal age and comprehension (9),
parents objected to being approached for research (8), baby transferred less than 7 days (3), and screening oversight (3). ** ‘Other’ reasons for
failure to consent included: language barrier (9), parent(s) overwhelmed (8), maternal illness (5), aged out prior to consent (4), baby died between
consent discussion and decision (2), maternal comprehension (2), baby Illness (1).
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pediatric physician scientists who are interested in pul-
monary investigation. Through small competitive grants,
trainees and non-NIH-funded junior faculty have access
to learning opportunities otherwise not available and de-
velop a time-limited research project that augments
PROP single site studies (Table 5). Over 3 years, 12
individuals have been funded and afforded the opportun-
ity to present their work at in-person steering committee
meetings, as well as at national pediatric and pulmonary
research meetings.
Discussion
In summary, the current dissociation between the diag-
nosis of BPD and respiratory outcomes/pathogenesis of
disease is due in part to a focus on hospitalization char-
acteristics rather than longer-term outcomes. In reality,
the continuum of disease and outcomes extend far
beyond the neonatal period, and it is in this context that
the respiratory consequences of prematurity need to be
defined and evaluated. The PROP represents a signifi-
cant investment by NHLBI to combine the multidiscip-
linary expertise of neonatologists, pediatric pulmonologists
and basic scientists to provide a balanced analysis of dis-
ease and care of pulmonary disease of prematurity
throughout the first year of life. The PROP will provide
an understanding of mechanisms, evolution and conse-
quences of lung disease in these preterm infants. It willalso create a repository of genetic and biological sam-
ples that will provide the seeds of new hypotheses and
future research in the complexity of gene-environment
interactions.
Appendix 1 Investigators and Research Staff
Cincinnati Children’s Hospital Medical Center
Investigators
Claire Chougnet, PhD
Robert Frenk, MD
James M. Greenberg, MD
William Hardie, MD
Alan H. Jobe MD, PhD
Karen McDowell, MD
Research staff
Barbara Alexander, RN
Tari Gratton, PA
Cathy Grigsby, BSN, CCRC
Beth Koch, BHS, RRT, RPFT
Kelly Thornton BS
Washington University School of Medicine site
Investigators
Thomas Ferkol, MD
Aaron Hamvas, MD2
Mark R. Holland, PhD
James Kemp, MD
Table 4 Demographics of enrolled PROP multicenter cohort
Enrolleda (N = 835)
Birth weight, grams (mean +/− SD) 900 +/− 240
Gestational age, weeks (mean +/− SD) 26.6 +/− 1.5
- 23 weeks, 0–6 days 34 (4%)
- 24 weeks, 0–6 days 108 (13%)
- 25 weeks, 0–6 days 129 (15%)
- 26 weeks, 0–6 days 170 (20%)
- 27 weeks, 0–6 days 201 (24%)
- 28 weeks, 0–6 days 193 (23%)
Multiple gestation 210 (25.1%)
- Twins 171 (81%)
- Triplets 35 (17%)
- Quadruplets 4 (2%)
Male 427 (51%)
Raceb
- Caucasian 486 (58.2%)
- African American 307 (36.8%)
- N. American Indian/Native Alaskan 1 (0.1%)
- Asian 20 (2.4%)
- Native Hawaiian/other Pacific islander 1 (0.1%)
- Multi-race 15 (1.8%)
- Other 5 (0.6%)
Ethnicityb
- Hispanic/Latino 92 (11%)
Inborn 728 (87.2%)
Outborn 105 (12.6%)
aPercentages may not add to 100 percent due to missing data for two babies
who were withdrawn four days after enrollment.
bRace and ethnicity uses a mutually exclusive definition.
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Phillip Tarr, MD
Gautam K. Singh, MD
Barbara Warner, MD
Research staff
Pamela Bates, CRT, RPFT, RPSGT
Claudia Cleveland, RRT
Julie Hoffmann, RN
Laura Linneman, RN
Jayne Sicard-Su, RN
Gina Simpson, RRT, CPFT
2Northwestern University Feinberg School of Medicine
University of California San Francisco site
Investigators
Philip L. Ballard MD, PhD
Roberta A. Ballard MD
David J. Durand MD2Eric C. Eichenwald MD 4
Roberta L. Keller MD
Amir M. Khan MD4
Leslie Lusk MD
Jeffrey D. Merrill MD 3
Dennis W. Nielson MD, PhD
Elizabeth E. Rogers MD
Research staff
Jeanette M. Asselin MS RRT-NPS2
Samantha Balan
Katrina Burson RN, BSN 4
Cheryl Chapin
Erna Josiah-Davis RN, NP3
Carmen Garcia RN, CCRP 4
Hart Horneman
Rick Hinojosa BSRT, RRT, CPFT-NPS 4
Christopher Johnson MBA, RRT 4
Susan Kelley RRT
Karin L. Knowles
M. Layne Lillie, RN, BSN 4
Karen Martin RN 4
Sarah Martin RN, BSN;
Julie Arldt-McAlister RN, BSN 4
Georgia E. McDavid RN 4
Lori Pacello RCP2
Shawna Rodgers RN, BSN 4
Daniel K. Sperry RN 4
2Children’s Hospital and Research Center Oakland,
Oakland CA
3Alta Bates Summit Medical Center, Berkeley CA
4University of Texas Health Science Center- Houston,
Houston TX
Vanderbilt University Medical Center site
Investigators
Judy Aschner, MD2
Candice Fike, MD
Scott Guthrie, MD3
Tina Hartert, MD
Nathalie Maitre, MD
Paul Moore, MD
Marshall Summar, MD4
Research Staff
Amy B Beller BSN
Mark O’ Hunt
Theresa J. Rogers, RN
Odessa L. Settles, RN, MSN, CM
Steven Steele, RN
Sharon Wadley, BSN, RN, CLS3
2Albert Einstein College of Medicine, Bronx NY
3Jackson-Madison County General Hospital, Jackson
TN
Table 5 Ancillary projects arising from PROP
Project Center Publications
PROP Scholars
Preventing attrition in follow-up Penn
Inter-rater reliability in physical exam Penn
Tracheal aspirate connective tissue mast cells in BPD Rochester [45]
Training in DLCO measurements Rochester
Treg impairment in preterm infants exposed to chorioamnionitis Cincinnati
Glutathionated hemoglobin as a biomarker for oxidant stress Vanderbilt [46]
RAGE signaling in BPD Vanderbilt
Periostin levels as a biomarker for BPD Indiana
Right ventricular strain measurements in evolving BPD Washington U [47-50]
Genetic contributions to BPD UCSF
Longitudinal lung clearance index measurements in premature infants UCSF
Oxidant stress and neurodevelopmental outcomes Vanderbilt
Variability in RIP Washington U [51]
Relationship between feeding desaturation, respiratory function and one year respiratory outcome in
preterm infants
Rochester
Respiratory pattern during physiologic challenges Washington U
RIP late preterm and term newborns Rochester, Washington U
Genetic Variants and Bronchopulmonary Dysplasia in Premature Infants Multi-center
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University of Rochester Medical Center/University at
Buffalo NY site
Investigators
Carl D’Angio, MD
Vasanth Kumar, MD
Tom Mariani, PhD
Gloria Pryhuber, MD
Clement Ren, MD
Anne Marie Reynolds, MD, MPH
Rita M. Ryan, MD2
Kristin Scheible, MD
Timothy Stevens, MD, MPH
Research staff
Shannon Castiglione, RN
Aimee Horan, LPN
Deanna Maffet, RN
Jane O’Donnell, PNP
Michael Sacilowski, MAT
Tanya Scalise, RN, BSN
Elizabeth Werner, MPH
Jason Zayac, BS
Heidie Huyck, BS
Valerie Lunger, MS
Kim Bordeaux, RRT
Pam Brown, RRTJulia Epping, AAS, RT
Lisa Flattery-Walsh, RRT
Donna Germuga, RRT, CPFT
Nancy Jenks, RN
Mary Platt, RN
Eileen Popplewell, RRT
Sandra Prentice, CRT
2Medical University of South Carolina, Charleston SC
Duke
Investigators
C. Michael Cotten, M.D.
Kim Fisher, Ph.D.
Jack Sharp, M.D.
Judith A. Voynow, M.D. 2
Research staff
Kim Ciccio, RN
2Virginia Commonwealth University
Indiana
Investigators
Stephanie Davis, MD
Brenda Poindexter, MD, MS 2
Research staff
Charles Clem, RRT
Susan Gunn, NNP, CCRC
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2Cincinnati Children’s Hospital Medical CenterUniversity of Pennsylvania, Perelman School of Medicine,
DCC site
Investigators
Jonas Ellenberg, PhD
Rui Feng, PhD
Howard Panitch, MD
Barbara Schmidt MD, MSc
Pamela Shaw, PhDResearch staff
Maria Blanco, BS
Denise Cifelli, MS
Sara DeMauro, MD
Melissa Fernando, MPH
Ann Tierney, BA, MSUniversity of Denver, Steering Committee Chair
Lynn M. Taussig, MDNHLBI program officer
Carol J. Blaisdell, MDAppendix 2
Institutional Review Board Protocols at individual PROP
sites
1. The University of Pennsylvania Data Coordinating
Center – 813839
2. Cincinnati University Hospital (11) - 2011-1664
3. Cincinnati Children’s Hospital Medical Center (12)
– 2011-1664
4. Cincinnati Good Samaritan’s Hospital (13) – 11139-
11-084
5. Washington University (21) – 201104267
6. University of California, San Francisco (31) – 10-
04838
a. Alta Bates (32) – 11-08-03
b. CHO (32) –2011-050
7. University of Texas, Houston (33) – HSC-MC-11-
0499
8. Vanderbilt University Monroe Caroll (41) - 110833
9. Jackson Madison County General Hospital (42) –
542
10. University of Rochester (51) – RSRB00037933
11. University of Buffalo (52) – 386479-1 DB # 2707
12. Duke University (61) – Pro 00025462
13. Indiana University (62) - 1201007831Additional files
Additional file 1: PROP biorepository lab specimen collection
guideline.
Additional file 2: Prematurity and respiratory outcomes program.
Eligibility and baseline data.
Additional file 3: Prematurity and respiratory outcomes program.
Daily growth and nutrition/daily medication data.
Additional file 4: Prematurity and respiratory outcomes program.
Comorbidities of prematurity.
Additional file 5: Prematurity and respiratory outcomes program.
Standard visit and follow up surveys.
Additional file 6: Prematurity and respiratory outcomes program.
Additional medication log and miscellaneous forms.
Additional file 7: Prematurity and respiratory outcomes program.
Noninvasive respiratory assessments [NIRA].
Additional file 8: Table S1. Infant pulmonary function test
measurements.
Additional file 9: PROP biospecimen access policy.
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